Total and Subtypes of Dietary Fat Intake and Its Association with Components of the Metabolic Syndrome in a Mediterranean Population at High Cardiovascular Risk

Alicia Julibert 1,2,3, Maria del Mar Bibiloni 1,2,3, Cristina Bouzas 1,2,3, Miguel Ángel Martínez-González 1,4,5, Jordi Salas-Salvadó 1,6, Dolores Corella 1,7, Maria Dolors Zomeño 1,8, Dora Romaguera 1,3, Jesús Vioque 9,10, Ángel M. Alonso-Gómez 7,11, Julia Wärnberg 1,12, J. Alfredo Martínez 1,13,14, Luis Serra-Majem 1,15, Ramon Estruch 1,16, Francisco J. Tinahones 1,17, José Lapetra 1,18, Xavier Pintó 1,19, José Lopez-Miranda 1,20, Laura García-Molina 10,21, José Juan Gaforio 10,22, Pilar Matía-Martín 23, Lidia Daimiel 24, Vicente Martín-Sánchez 25,26, Josep Vidal 27, Clotilde Vázquez 1,28, Emili Ros 1,29, Estefanía Toledo 1,4, Nerea Becerra-Tomás 1,6, Olga Pörtoles 1,7, Karla A. Pérez-Vega 1,8, Miquel Fiol 1,3, Laura Torres-Collado 9,10, Lucas Tojal-Sierra 2,11, Rosa Carabaño-Moral 1,30, Itziar Abete 1,13, Almudena Sanchez-Villegas 1,15, Rosa Casas 1,16, María Rosa Bernal-López 1,17, José Manuel Santos-Lozano 1,18, Ana Galera 1,19, Lucía Ugarriza 1,2,3, Miguel Ruiz-Canela 1,4, Nancy Babio 1,6, Oscar Coltell 1,31, Helmut Schröder 8,10, Jadwiga Konieczna 1,3, Domingo Orozco-Beltrán 9,10, Carolina Sorto-Sánchez 1,11, Sonia Eguaras 1,4, Laura Barrubés 1,6, Montserrat Fitó 1,8, Josep A. Tur 1,2,3,* and PREDIMED-PLUS Investigators

1 CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
2 Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands, 07122 Palma de Mallorca, Spain
3 Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
4 Department of Preventive Medicine and Public Health, IdISNA, University of Navarra, 31008 Pamplona, Spain
5 Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA
6 Human Nutrition Unit, Biochemistry and Biotechnology Department, IISPV, Universitat Rovira i Virgili, 43201 Reus, Spain
7 Department of Preventive Medicine, University of Valencia, 46100 Valencia, Spain
8 Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Médica (IMIM), 08003 Barcelona, Spain
9 Miguel Hernández University, ISABIAL-FISABIO, 46020 Alicante, Spain
10 CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
11 Department of Cardiology, OSI ARABA, University Hospital Araba, University of the Basque Country UPV/EHU, 01009 Vitoria-Gasteiz, Spain
12 Department of Nursing, School of Health Sciences, University of Málaga-IBIMA, 29071 Málaga, Spain
13 Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain
14 Cardiometabolics Nutrition Group, IMDEA Food, CEI UAM + CSIC, 28049 Madrid, Spain
15 Institute for Biomedical Research, University of Las Palmas de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain
16 Department of Internal Medicine, IDIBAPS, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
17 Virgen de la Victoria Hospital, Department of Endocrinology, University of Málaga, 29010 Málaga, Spain
18 Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, 41013 Sevilla, Spain
19 Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, 08907 Barcelona, Spain

Nutrients 2019, 11, 1493; doi:10.3390/nu11071493 www.mdpi.com/journal/nutrients
Abstract: Background: The effect of dietary fat intake on the metabolic syndrome (MetS) and in turn on cardiovascular disease (CVD) remains unclear in individuals at high CVD risk. Objective: To assess the association between fat intake and MetS components in an adult Mediterranean population at high CVD risk. Design: Baseline assessment of nutritional adequacy in participants \( n = 6560, \) men and women, 55–75 years old, with overweight/obesity and MetS in the PREvención con DIeta MEDiterránea (PREDIMED)-Plus randomized trial. Methods: Assessment of fat intake (total fat, monounsaturated fatty acids: MUFA, polyunsaturated fatty acids: PUFA, saturated fatty acids: SFA, trans-fatty acids: trans-FA, linoleic acid, \( \alpha \)-linolenic acid, and \( \omega \)-3 FA) using a validated food frequency questionnaire, and diet quality using 17-item Mediterranean dietary questionnaire and fat quality index (FQI). Results: Participants in the highest quintile of total dietary fat intake showed lower intake of energy, carbohydrates, protein and fiber, but higher intake of PUFA, MUFA, SFA, TFA, LA, ALA and \( \omega \)-3 FA. Differences in MetS components were found according to fat intake. Odds (5th vs. 1st quintile): hyperglycemia: 1.3–1.6 times higher for total fat, MUFA, SFA and \( \omega \)-3 FA intake; low high-density lipoprotein cholesterol (HDL-c): 1.2 higher for LA; hypertriglyceridemia: 0.7 lower for SFA and \( \omega \)-3 FA intake. Conclusions: Dietary fats played different role on MetS components of high CVD risk patients. Dietary fat intake was associated with higher risk of hyperglycemia.

Keywords: fatty acids; dietary fat; fat intake; Mediterranean diet; cardiovascular disease risk

1. Introduction

Obesity and the ensuing metabolic syndrome (MetS) are becoming an epidemic. If recent secular trends continue unabated, up to 20% of the world’s adult population (1.2 billion individuals) is expected to be obese by 2030. The prevalence of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) are also expected to increase by 54% and 22%, respectively [1–4].

In an effort to tackle the problem of obesity, and in turn cardiovascular risk, nutritional guidelines recommended a global limit on total fat intake, inevitably resulting in an increased intake of simple carbohydrates and decreased intake of healthy unsaturated fatty acids (UFA) [5]. Dietary UFA may prevent the development of metabolic diseases such as T2DM, and reduce cardiovascular events [6]. Moreover, the presumed relationship between dietary saturated fatty acids (SFA) and an increased risk
of coronary heart disease (CHD) or CVD may depend on the complexity of these fatty acids and the food matrix in which they are present [7].

Evidence currently available resulting from the dietary fat interventions does not support the current dietary fat guidelines [8]. In 2015, the Dietary Guidelines Advisory Committee emphasized the importance of healthful, food-based diet patterns, revisiting the role of fat in health [9].

The Mediterranean diet (MedDiet) is characterized by high intakes of plant foods (fruits, vegetables, legumes, nuts, and whole grains) and olive oil as the principal source of dietary lipids [10]. This dietary pattern seems to ameliorate metabolic risk factors defining the MetS [11] (and reduce the incidence of cardiovascular events, breast cancer, and T2DM compared with any other diet [12,13].

The PREDenciön con DIeta MEDiterránea (PREDIMED)-Plus study provides a unique opportunity to assess the association between fat intake and MetS components in an adult Mediterranean population at high CVD risk.

2. Methods

2.1. Study Design

This research represents a cross-sectional study on baseline data of the PREDIMED-Plus trial. PREDIMED-Plus study is an ongoing 6-year multicenter, parallel-group, randomized trial conducted in 23 Spanish recruiting centers to evaluate the effect of an intensive weight loss program based on an energy-restricted traditional Mediterranean diet (erMedDiet), physical activity promotion, and behavioral support on hard cardiovascular events, in comparison with an usual care intervention only with energy-unrestricted MedDiet (control group) and any advice to increase physical activity. The PREDIMED-Plus study protocol is fully described in a publication by Martinez-González et al. [14] and available at http://predimedplus.com/. The trial was registered in 2014 at the International Standard Randomized Controlled Trial (ISRCT; http://www.isrctn.com/ISRCTN89898870) with number 89898870.

2.2. Participants, Recruitment, and Randomization

Eligible participants were community-dwelling adults men aged between 55 and 75 years and women between 60 and 75 years, without documented history of CVD at enrollment, who were overweight or obese (body mass index [BMI] ≥27 and <40 kg/m²) and meeting at least 3 criteria for the MetS according to the updated harmonized definition of the International Diabetes Federation and the American Heart Association and National Heart, Lung and Blood Institute [15]: Abdominal obesity for European individuals (WC ≥88 cm in women and ≥102 cm in men), hypertriglyceridemia (≥150 g/dL) or drug treatment for high plasma triglycerides (TG) concentrations, low high-density lipoprotein cholesterol (HDL-cholesterol; ≤50 mg/dL in women and ≤40 mg/dL in men), high blood pressure (systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg or antihypertensive drug treatment), or high fasting plasma glucose (≥100 mg/dL) or drug treatment for T2DM.

From 5 September 2013 to 31 October 2016, a total of 6874 participants were recruited in 23 Spanish centers (universities, hospitals, and research institutes).

The present analysis included 6560 subjects (3387 men and 3173 women (Figure 1) were included). We excluded those participants (n = 314) recording extreme total energy intakes (<500 or >3500 kcal/day in women or <800 or >4000 kcal/day in men) [16]. We also excluded participants who did not respond to all the physical activity questionnaires (n = 14) and participants reporting outliers for total physical activity expressed as metabolic equivalents of task [METs-min/week (at 3 or more standard deviations [SD] from the mean for each sex)].
2.3. Ethics

All participants provided written informed consent, and the study protocol and procedures were approved according to the ethical standards of the Declaration of Helsinki by all the participating institutions.

2.4. Dietary Assessment

Registered dietitians collected data on dietary intake at baseline with a semiquantitative 143-item food frequency questionnaire (FFQ), assessing dietary habits over the previous 12 months, repeatedly validated in Spain [17]. Detailed information about the development, reproducibility, and validity of FFQ in the PREDIMED cohort has been previously reported [17–19]. For each item, a typical portion size was included and consumption frequencies were registered in 9 categories that ranged from “never or almost never” to “≥6 times/day”. Energy and nutrient intakes were calculated as frequency multiplied by nutrient composition of specified portion size for each food item, using a computer program based on available information in food composition tables [20–23]. The selected frequency item was converted to a daily intake. For example, if a response was 5–6 times a week, it was converted to 0.78 servings per day (5.5 week/7 days) [19]. For each FFQ food item, we estimated the average amount of food consumed (grams), the average total energy intake, and the average intake of a set of macro-and micronutrients by computing the mean of the values for the individual foods assigned to that item [24].

We also considered the total nutrient intake, the average intake of micronutrients from dietary supplements declared by participants in the FFQ.

2.5. Determination of Fat Intake

Dietary intake of total fat and fatty acids: Monounsaturated (MUFA), polyunsaturated (PUFA), and saturated (SFA), trans-fatty acid (TFA), linoleic acid (LA), α-linolenic acid (ALA), and marine ω-3 fatty acid (ω-3 FA) were estimated.

On the other hand, the fat quality index (FQI) was calculated as previously described [16]. Briefly, the FQI was calculated using the ratio (MUFA + PUFA)/(SFA + TFA) as a continuous variable.

Participants were also administered a 17-item Mediterranean dietary questionnaire, a modified version of the previously validated questionnaire used in the PREDIMED trial [25]. Compliance with each of the 17 food habits reflecting an erMedDiet was scored with 1 point and 0 points otherwise.
Therefore, a score ranging from 0–17 points, with 0 meaning no adherence and 17 meaning maximum adherence, was developed.

2.6. Physical Activity

Physical activity was measured using the Rapid Assessment of Physical Activity Questionnaires (RAPA-1 and RAPA-2) [26] and the validated Minnesota-REGICOR (Registre Gironí del Cor) Short Physical Activity questionnaire [27–29]. Metabolic Equivalent of tasks (MET) are calculated by multiplying the intensity (showed by the MET-score) and the duration spent on that activity (measured in minutes). The intensity was assigned based on the compendium of physical activity [30]. Detailed information about the development and reproducibility has been reported [31].

2.7. Anthropometric and Blood Pressure Measurements

Anthropometric variables were measured by trained personnel according to the PREDIMED-Plus protocol. Weight and height were measured with high-quality electronic calibrated scales and a wall-mounted stadiometer, respectively. BMI was calculated as weight in kilograms divided by the square of height in meters. Waist circumference (WC) was measured halfway between the last rib and the iliac crest by using an anthropometric tape. Blood pressure was measured in triplicate with a validated semi-automatic oscillometer (Omron HEM-705CP) after 5 min of rest in-between measurements while the participant was in a seated position. All anthropometric variables were determined in duplicate, except for blood pressure (in triplicate).

2.8. Blood Collection and Analysis

Samples of fasting blood and urine were also collected after an overnight fast at baseline. Biochemical analyses were performed on fasting plasma glucose, total cholesterol, low high-density lipoprotein cholesterol (HDL-c,) and triglyceride (TG) concentrations in local laboratories using standard enzymatic methods.

2.9. Other Health Outcomes

At the baseline visit, additional information related to sociodemographic and lifestyle aspects (education level, civil status, smoking habits, alcohol intake, physical activity, individual and family medical history, and current medication use) was collected.

2.10. Statistical Analyses

Analyses were performed with the SPSS statistical software package version 25.0 (SPSS Inc., Chicago, IL, USA). We used the PREDIMED-Plus baseline database generated in August 2017. Overall, 8 nutrients were examined (total fat, MUFA, PUFA, SFA, TFA, LA, ALA and ω-3 FA). Following standard procedures, nutrient intakes were energy-adjusted using the residual method [32,33] and then converted into quintiles. Qualitative variables were expressed as percentages and quantitative variables were expressed as means and SD. Pearson’s chi-square tests and analysis of variance (ANOVA) (for categorical and continuous variables, respectively) were used to compare differences across quintile groups. We used the Bonferroni method to test multiple comparisons across quintile groups. Logistic regression analyses with the calculation of corresponding odds ratio (OR) and the 95% confidence interval (95% CI) were also used to assess the association between MetS components and quintiles of dietary fat and fat subtypes. Results were adjusted for sex, age (continuous variable), BMI (continuous variable), energy intake (continuous variable), alcohol intake (continuous variable), adherence to the MedDiet (continuous variables), total physical activity (continuous variable, expressed as MET·min/week), smoking habit (categorized variable: Current, former and never) and education level (categorized variable: Primary, secondary, university, or graduate) to control for potential confounders. Results were considered statistically significant if p-value (2 tailed) <0.05.
3. Results

The general characteristics of the study population across quintiles of total and several subtypes of dietary fat intake are shown in Table 1. The percentage of energy from total dietary fat of the participants ranged from 30.5 (SD: 2.9) in the lowest to 48.5 (SD: 3.3) in the highest quintile (mean: 39.4%, SD: 6.5). Specifically, women had significantly higher intakes of total fat, PUFA, SFA, LA and ALA, but lower in the highest quintile of TFA intake. BMI was significantly lower in the highest vs. lowest quintile of total PUFA (0.3 ± 0.13 kg/m$^2$, $p < 0.001$), LA (0.3 ± 0.13 kg/m$^2$, $p = 0.020$) and ALA (0.6 ± 0.13 kg/m$^2$, $p < 0.001$). Conversely, BMI was significantly higher in the highest quintile of total fat and SFA. Mean physical activity (expressed as METs·min/week) was significantly higher in the highest quintile of MUFA, PUFA, ALA and ω-3 FA intakes, but lower in the highest quintile of SFA and TFA intakes. Statistical significant differences in education level were also found between quintile groups of total fat, MUFA, SFA, TFA, LA, and ω-3 FA intake. Statistical significant differences in smoking habits were also found between quintile groups of PUFA, SFA, TFA, ALA, and ω-3 FA.

The nutrient intake and food consumption of the participants as per quintiles of total and several subtypes of dietary fat were also assessed (Tables 2 and 3). Participants in the highest quintile of total dietary fat intake had significantly lower intakes of energy, carbohydrates, protein, and fiber, but higher intakes of all subtypes of fat (PUFA, MUFA, SFA, TFA, LA, ALA, and ω-3 FA). Participants in the highest quintiles of PUFA, LA, and ALA intake had lower TFA and cholesterol intakes but higher fiber intake (except for ALA quintiles). Fiber intake was also higher in participants in the highest quintile of ω-3 FA intake. Participants in the highest quintile of ω-3 FA and SFA intake had significantly higher intake of protein and cholesterol. Cholesterol intake was also higher in participants in the highest quintile of TFA. FQI increased significantly with increasing quintiles of total and all subtypes of dietary intake except for SFA and TFA.
Table 1. Lifestyle characteristics and Metabolic Syndrome components according to total dietary fat and specific types of fat (g/day).

| Participants, n | Total Fat | MUFA | PUFAs | SFAs |
|----------------|----------|------|-------|------|
|                | Q1       | Q5   | p Value | Q1       | Q5   | p Value | Q1       | Q5   | p Value |
| Age, years     | 1294     | 1291 |         | 1312     | 1312 |         | 1312     | 1312 |         |
| Women, %       | 65.1 ± 5.0 | 64.7 ± 4.9 | 0.164 | 65.1 ± 5.0 | 64.8 ± 4.8 | 0.088 | 64.7 ± 5.0 | 65.3 ± 4.9 | 0.016 | 65.2 ± 5.0 | 64.5 ± 5.0 | <0.001 |
| BMI, kg/m²     | 32.4 ± 3.4 | 32.8 ± 3.5 | NS     | 0.005 | 32.4 ± 3.4 | 32.7 ± 3.6 | 0.226 | 32.6 ± 3.4 | 32.3 ± 3.4 | <0.001 | 32.3 ± 3.3 | 32.8 ± 3.5 | <0.001 |
| Smoking habit, % |          |      |        |        |        |        |        |        |        |        |        |        |        |
| Current        | 11.6     | 12.0 |         | 11.1 | 12.0 |         | 14.1 | 11.5 |         | 11.2 | 12.5 |         |        |        |
| Former         | 44.0     | 44.6 | 0.820   | 42.2 | 44.9 | 0.446   | 47.1 | 41.7 | 0.002   | 46.7 | 45.2 | 0.021   |        |        |
| Never          | 44.5     | 45.4 |         | 46.7 | 43.1 |         | 38.8 | 46.8 |         | 42.1 | 42.3 |         |        |        |
| Education, %   |          |      |        |        |        |        |        |        |        |        |        |        |        |
| Primary        | 52.3     | 42.6 |         | 52.8 | 44.5 |         | 46.2 | 48.7 |         | 50.3 | 40.3 |         |        |        |
| Secondary      | 28.3     | 30.3 | <0.001  | 27.7 | 29.6 | 0.001   | 30.6 | 28.2 | 0.268   | 27.8 | 34.7 | <0.001  |        |        |
| University or graduate | 19.4 | 27.1 |         | 19.5 | 25.9 |         | 23.2 | 23.1 |         | 21.9 | 25.0 |         |        |        |

| Total physical activity, n † |        |        |        |        |        |        |        |        |        |        |        |        |
| MET min/week † | 2394 ± 2024 | 2440 ± 1876 | 0.912 | 2396 ± 1965 | 2486 ± 1883 | 0.027 | 2322 ± 2199 | 2529 ± 1875 | 0.025 | 2628 ± 2042 | 2281 ± 1918 | <0.001 |
| Males          | 2796 ± 2268 | 2632 ± 2029 | 0.233 | 2745 ± 2177 | 2744 ± 2029 | 0.146 | 2674 ± 2231 | 2838 ± 2088 | 0.366 | 3053 ± 2256 | 2572 ± 2163 | 0.001 |
| Females        | 1868 ± 1500 | 2233 ± 1672 | 0.004 | 1970 ± 1569 | 2213 ± 1673 | 0.003 | 1799 ± 1513 | 2205 ± 1559 | <0.001 | 2039 ± 1518 | 1950 ± 1531 | 0.458 |

| MetS components, % |        |        |        |        |        |        |        |        |        |        |        |        |
| High blood pressure | 93.0 | 91.7 | 0.328 | 92.5 | 91.3 | 0.300 | 92.8 | 92.0 | 0.724 | 92.5 | 91.3 | 0.495 |
| Hyperglycaemia     | 73.9 | 80.3 | <0.001 | 74.0 | 80.0 | <0.001 | 73.3 | 75.6 | 0.014 | 73.2 | 78.3 | 0.032 |
| Hypertension/heart disease | 58.7 | 56.6 | 0.139 | 57.0 | 56.0 | 0.889 | 56.8 | 55.2 | 0.111 | 57.9 | 53.4 | 0.120 |
| Low HDL-cholesterol | 38.7 | 44.4 | 0.004 | 40.4 | 44.7 | 0.171 | 40.9 | 46.3 | 0.015 | 40.2 | 42.1 | 0.068 |
| Abdominal obesity  | 95.2 | 96.7 | 0.180 | 95.4 | 96.6 | 0.317 | 95.6 | 96.6 | 0.657 | 95.5 | 96.4 | 0.390 |
| Males             | 92.0 | 94.3 | 0.387 | 92.2 | 94.0 | 0.386 | 93.1 | 94.2 | 0.704 | 92.6 | 93.8 | 0.503 |
| Females           | 99.5 | 99.4 | 0.944 | 99.3 | 99.4 | 0.453 | 99.2 | 99.2 | 0.543 | 99.5 | 99.3 | 0.990 |

| Trans FA | Linoleic acid | Linolenic acid | ω-3 FA |
|----------|---------------|---------------|--------|
| Participants, n | 1312 | 1312 | 1312 | 1312 | 1312 | 1312 | 1312 | 1312 |
| Age, years | 65.8 ± 4.7 | 64.0 ± 5.1 | <0.001 | 64.6 ± 5.0 | 65.4 ± 4.9 | 0.001 | 63.9 ± 5.0 | 65.6 ± 4.8 | <0.001 | 65.1 ± 5.0 | 65.1 ± 4.8 | 0.345 |
| Women, % | 60.9 | 37.6 | <0.001 | 40.2 | 48.2 | <0.001 | 29.9 | 56.6 | <0.001 | 47.6 | 51.2 | 0.217 |
| BMI, kg/m² | 32.3 ± 3.4 | 32.6 ± 3.5 | 0.074 | 32.6 ± 3.4 | 32.3 ± 3.5 | NS | 0.020 | 32.7 ± 3.4 | 32.1 ± 3.3 | *<0.001 | 32.7 ± 3.4 | 32.5 ± 3.4 | 0.387 |
| Smoking habit, % |      |        |        |        |        |        |        |        |        |        |        |        |
| Current | 8.9 | 14.0 |         | 14.0 | 12.2 |         | 16.7 | 9.5 |         | 14.4 | 10.3 |         |        |        |
| Former  | 39.7 | 47.0 | <0.001 | 47.1 | 41.6 | 0.007 | 49.6 | 39.4 | <0.001 | 42.4 | 45.1 | 0.003 |
| Never   | 51.4 | 39.0 |         | 39.0 | 46.0 |         | 33.8 | 51.1 |         | 43.2 | 44.6 |         |        |        |
| Education, % |      |        |        |        |        |        |        |        |        |        |        |        |
| Primary | 57.0 | 41.3 |         | 44.1 | 50.5 |         | 46.6 | 50.1 |         | 54.2 | 47.2 |         |        |        |
| Secondary | 24.6 | 31.6 | <0.001 | 30.8 | 28.1 | 0.003 | 29.9 | 27.6 | 0.286 | 27.4 | 27.8 | <0.001 |        |        |
| University or graduate | 18.4 | 27.1 |         | 25.2 | 21.4 |         | 23.5 | 22.3 |         | 18.3 | 25.0 |         |        |        |
Table 1. Cont.

|                          | Q1       | Q5       | p Value | Q1       | Q5       | p Value | Q1       | Q5       | p Value | Q1       | Q5       | p Value |
|--------------------------|----------|----------|---------|----------|----------|---------|----------|----------|---------|----------|----------|---------|
| Total physical activity, n † | 1248     | 1230     | 1229    | 1249     | 1216     | 1251    | 1237     | 1253     |         |          |          |         |
| Total physical activity, MET min/week † | 2572 ± 1924 | 2373 ± 1977 | 0.075 | 2445 ± 2098 | 2499 ± 1884 | 0.130 | 2454 ± 2099 * | 2621 ± 1961 * | 0.002 | 2227 ± 1952 * | 2673 ± 2038 * | <0.001 |
| Males                    | 3107 ± 2208 * | 2580 ± 2168 * | <0.001 | 2801 ± 2332 | 2852 ± 2095 | 0.491 | 2695 ± 2241 * | 3080 ± 2230 * | 0.015 | 2657 ± 2168 | 2983 ± 2341 NS | 0.048 |
| Females                  | 2225 ± 1624 * | 2027 ± 1590 * | 0.006 | 1908 ± 1539 | 2114 ± 1534 | 0.191 | 1852 ± 1541 * | 2262 ± 1636 * | <0.001 | 1744 ± 1541 * | 2372 ± 1639 * | <0.001 |
| MetS components, n (%)    |          |          |        |          |          |         |          |          |         |          |          |         |
| High blood pressure      | 91.9     | 92.3     | 0.108  | 92.9     | 92.0     | 0.313   | 92.9     | 91.6     | 0.566   | 91.8     | 91.5     | 0.068   |
| Hyperglycaemia           | 76.2     | 75.2     | 0.232  | 73.4     | 75.2     | 0.047   | 74.1     | 75.8     | 0.373   | 74.0     | 79.0     | 0.020   |
| Hypertriglyceridemia     | 55.2     | 55.6     | 0.611  | 55.6     | 56.4     | 0.847   | 57.2     | 53.2     | 0.186   | 59.1     | 50.8     | <0.001  |
| Low HDL-cholesterol      | 43.5     | 42.2     | 0.863  | 39.9     | 47.0     | <0.001  | 41.5     | 44.7     | 0.586   | 45.8     | 41.1     | 0.147   |
| Abdominal obesity        | 95.9     | 95.7     | 0.360  | 95.6     | 96.3     | 0.850   | 94.4     | 97.0     | 0.009   | 95.8     | 97.1     | 0.179   |
| Males                    | 90.6     | 91.7     | 0.170  | 93.1     | 93.5     | 0.948   | 92.2     | 94.0     | 0.414   | 92.6     | 94.7     | 0.338   |
| Females                  | 99.2     | 99.2     | 0.587  | 99.2     | 99.2     | 0.479   | 99.7     | 99.2     | 0.343   | 99.4     | 99.4     | 0.210   |

Abbreviations: BMI, body mass index; FA, fatty acids; HDL-cholesterol, high density lipoprotein cholesterol; MetS, Metabolic Syndrome; MET, metabolic equivalent of task; MUFAs monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated fatty acids. All values are means ± SDs unless otherwise indicated. All quartiles were included in the analysis. Pearson’s chi-square test was used for categorical variables, and 1-factor ANOVA was used for continuous variables. *p < 0.05 for between-group changes, after adjustment for multiple comparisons with the Bonferroni method. **No statistical significance after post hoc test. † Participants who not responded the physical activity questionnaires and participants reporting outliers for total physical activity expressed as MET-min/week (at 3 or more standard deviations from the mean) were excluded from the analysis (i.e., 154 men and 196 women).
**Table 2. Nutrient intake according to total dietary fat and specific types of fat (g/day).**

| Nutrient                          | Total Fat          | MUFAs          | PUFAs          | SFAs          | PUFAs          |
|-----------------------------------|--------------------|----------------|----------------|---------------|----------------|
|                                   | Q1     | Q5   | p Value | Q1     | Q5   | p Value | Q1     | Q5   | p Value | Q1     | Q5   | p Value |
| Participants, n                   |        |      |         |        |      |         |        |      |         |        |      |         |
| Energy intake, kcal/day           | 1294   | 1291 |         | 1312   | 1312 |         | 1312   | 1312 |         | 1312   | 1312 |         |
| Carbohydrate intake, % total energy | <0.001  | 0.001 | <0.001  | <0.001  | 0.001 | <0.001  | <0.001  | 0.001 | <0.001  | <0.001  | 0.001 | <0.001  |
| Fat intake, % total energy        | 2446 ± 579 *   | 2432 ± 509 *  | <0.001  | 2441 ± 594 * | 2417 ± 516 *  | <0.001  | 2539 ± 534 *| 2498 ± 517 *  | <0.001  | 2532 ± 533 *| 2456 ± 551 *| <0.001  |
| Protein intake, % total energy    | 48.6 ± 5.4 *   | 33.3 ± 4.3 *  | <0.001  | 48.0 ± 5.6 *| 34.1 ± 4.9 *  | <0.001  | 45.7 ± 6.5 *| 37.7 ± 6.2 *  | <0.001  | 46.3 ± 6.3 *| 36.9 ± 5.7 *| <0.001  |
| Protein intake, % total energy    | 16.7 ± 3.0 *   | 15.9 ± 2.5 *  | <0.001  | 17.0 ± 3.0 *| 15.7 ± 2.4 *  | <0.001  | 16.3 ± 2.7 *| 16.2 ± 2.7 *  | <0.001  | 15.9 ± 2.7 *| 16.7 ± 2.7 *| <0.001  |
| Fat intake, % total energy        | 30.5 ± 2.9 *   | 48.5 ± 3.3 *  | <0.001  | 31.4 ± 3.9 *| 47.6 ± 4.1 *  | <0.001  | 33.7 ± 5.1 *| 43.7 ± 5.9 *  | <0.001  | 33.5 ± 5.1 *| 44.8 ± 5.5 *| <0.001  |
| PUFA, % total energy              | 5.0 ± 1.3 *    | 7.8 ± 2.0 *   | <0.001  | 5.5 ± 1.9 *| 7.4 ± 1.6 *   | <0.001  | 4.3 ± 0.5 *| 9.1 ± 1.5 *   | <0.001  | 6.0 ± 1.8 *| 6.4 ± 1.8 *| <0.001  |
| MUFAs, % total energy             | 14.8 ± 2.2 *   | 26.2 ± 3.5 *  | <0.001  | 14.3 ± 1.8 *| 26.9 ± 2.9 *  | <0.001  | 17.0 ± 3.2 *| 22.2 ± 5.0 *  | <0.001  | 17.5 ± 4.1 *| 22.7 ± 4.4 *| <0.001  |
| SFA, % total energy               | 8.2 ± 1.3 *    | 11.7 ± 1.9 *  | <0.001  | 8.7 ± 1.8 *| 11.0 ± 1.9 *  | <0.001  | 9.6 ± 2.2 *| 10.0 ± 1.8 *  | <0.001  | 7.5 ± 0.9 *| 12.8 ± 1.4 *| <0.001  |
| Trans FA, g/day                   | 0.52 ± 0.3 *   | 0.71 ± 0.5 *  | <0.001  | 0.57 ± 0.4 *| 0.63 ± 0.4 *  | <0.001  | 0.66 ± 0.4 *| 0.59 ± 0.4 *  | <0.001  | 0.39 ± 0.3 *| 0.94 ± 0.5 *| <0.001  |
| Linoleic acid, g/day              | 11.1 ± 4.5 *   | 17.4 ± 6.4 *  | <0.001  | 12.0 ± 5.7 *| 16.3 ± 5.4 *  | <0.001  | 9.8 ± 3.1 *| 20.8 ± 5.3 *  | <0.001  | 13.7 ± 5.4 *| 14.3 ± 5.8 *| <0.001  |
| Linolenic acid, g/day             | 1.2 ± 0.6 *    | 1.8 ± 0.8 *   | <0.001  | 1.3 ± 0.7 *| 1.7 ± 0.7 *   | <0.001  | 1.3 ± 0.3 *| 2.3 ± 0.8 *   | <0.001  | 1.4 ± 0.7 *| 1.6 ± 0.6 *| <0.001  |
| ω-3 FA, g/day                     | 0.19 ± 0.9 *   | 1.6 ± 0.6 *   | <0.001  | 1.52 ± 0.9 *| 1.61 ± 0.8 *  | <0.001  | 1.59 ± 0.8 *| 1.72 ± 0.8 *  | <0.001  | 1.59 ± 0.9 *| 1.55 ± 0.8 | <0.001  |
| FQI score                         | 2.4 ± 0.5 *    | 3.0 ± 0.7 *   | <0.001  | 2.29 ± 0.5 *| 3.15 ± 0.7 *  | <0.001  | 2.26 ± 0.5 *| 3.16 ± 0.7 *  | <0.001  | 3.12 ± 0.7 *| 2.24 ± 0.4 *| <0.001  |
| Cholesterol (mg/day)              | 27 ± 9 ± 2. *  | 23 ± 8 ± 2. * | <0.001  | 27 ± 9 ± 2. *| 25 ± 8 ± 2. * | <0.001  | 26 ± 8 ± 2. *| 28 ± 9 ± 1. * | <0.001  | 31 ± 10 ± 3. *| 22 ± 6 ± 2. *| <0.001  |
| Linoleic acid ultra-3 FA          | 365 ± 113 *   | 399 ± 119 *   | <0.001  | 378 ± 122 | 380 ± 115 | 0.182 | 394 ± 134 | 381 ± 111 | <0.001 | 346 ± 106 | 438 ± 125 | <0.001 |
| Linolenic acid ultra-3 FA         | 29 ± 10 ± 8. * | 23 ± 8 ± 7.7 | <0.001  | 27 ± 9 ± 2. *| 25 ± 8 ± 4. * | <0.001  | 26 ± 8 ± 9.0 | 28 ± 9 ± 1.1 | <0.001  | 31 ± 10 ± 3. *| 22 ± 6 ± 2. *| <0.001  |

Abbreviations: FA, fatty acids; FQI, fat quality index; MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated fatty acids. All values are means ± SDs unless otherwise indicated. All quartiles were included in the analysis. Pearson's chi-square test was used for categorical variables, and 1-factor ANOVA was used for continuous variables. *p < 0.05 for between-group changes, after adjustment for multiple comparisons with the Bonferroni method.
| Dietary items          | Total Fat (g/day) | MUFA (g/day) | PFA (g/day) | SFAs (g/day) | p Value | Total Fat (g/day) | MUFA (g/day) | PFA (g/day) | SFAs (g/day) | p Value | Total Fat (g/day) | MUFA (g/day) | PFA (g/day) | SFAs (g/day) | p Value | Total Fat (g/day) | MUFA (g/day) | PFA (g/day) | SFAs (g/day) | p Value |
|-----------------------|-------------------|--------------|-------------|-------------|----------|-------------------|--------------|-------------|-------------|----------|-------------------|--------------|-------------|-------------|----------|-------------------|--------------|-------------|-------------|----------|
| Fruits, g/day         | 420 ± 259 *       | 305 ± 170 *  | <0.001      | 404 ± 239 * | <0.001  | 327 ± 183 *       | <0.001       | 383 ± 238 * | <0.001      | 370 ± 205 * | <0.001  | 444 ± 258 *       | <0.001       | 448 ± 259 *  | 289 ± 172 *  | <0.001  |
| Vegetables, g/day     | 333 ± 149 *       | 310 ± 126 *  | <0.001      | 331 ± 148 * | 0.001   | 320 ± 132 *       | <0.001       | 319 ± 144 * | 0.001     | 340 ± 138 * | <0.001  | 356 ± 154 *       | <0.001       | 352 ± 129 *  | 292 ± 129 *  | <0.001  |
| Legumes, g/day        | 22 ± 13 *         | 19 ± 10 *    | <0.001      | 22 ± 13 *   | <0.001  | 20 ± 10 *         | <0.001       | 20 ± 12 *   | 0.004     | 21 ± 11 *   | 0.001   | 23 ± 13 *         | <0.001       | 19 ± 10 *    | 0.001       | <0.001  |
| Olive oil, g/day      | 27 ± 13 *         | 35 ± 14 *    | <0.001      | 23 ± 10 *   | <0.001  | 57 ± 13 *         | <0.001       | 36 ± 15 *   | <0.001    | 41 ± 19 *   | <0.001  | 38 ± 16 *         | <0.001       | 43 ± 18 *    | <0.001      | <0.001  |
| Nuts, g/day           | 10 ± 12 *         | 22 ± 23 *    | <0.001      | 10 ± 12 *   | <0.001  | 24 ± 24 *         | <0.001       | 5 ± 6 *     | <0.001    | 34 ± 23 *   | <0.001  | 17 ± 20 *         | <0.001       | 13 ± 15 *    | <0.001      | <0.001  |
| Total fish, g/day     | 97 ± 49 *         | 105 ± 47 *   | <0.001      | 99 ± 50     | 0.022   | 103 ± 46 ^NS^     | <0.001       | 104 ± 50 *  | 0.017     | 99 ± 47 *   | 0.001   | 104 ± 50 *        | 0.001       | 105 ± 47 *   | 0.001       | <0.001  |
| Total cereals, g/day  | 203 ± 95 *        | 110 ± 52 *   | <0.001      | 190 ± 94 *  | <0.001  | 118 ± 59 *        | <0.001       | 196 ± 91 *  | <0.001    | 138 ± 69 *  | <0.001  | 208 ± 93 *        | <0.001       | 118 ± 60 *   | <0.001      | <0.001  |
| Dairy products, g/day | 302 ± 177 *       | 302 ± 177 *  | <0.001      | 204 ± 120 * | <0.001  | 292 ± 175 *       | <0.001       | 418 ± 223 * | <0.001    | 324 ± 197 * | <0.001  | 348 ± 226 *        | <0.001       | 267 ± 202 *  | <0.001      | <0.001  |
| Total meat, g/day     | 136 ± 57 *        | 156 ± 61 *   | <0.001      | 140 ± 59 *  | <0.001  | 148 ± 56 *        | <0.001       | 132 ± 59 *  | <0.001    | 146 ± 59 *  | <0.001  | 130 ± 52 *        | <0.001       | 172 ± 62 *   | <0.001      | <0.001  |
| Cookies, g/day        | 30 ± 35 *         | 25 ± 27 *    | <0.001      | 32 ± 35 *   | <0.001  | 23 ± 25 *         | <0.001       | 36 ± 39 *   | <0.001    | 25 ± 27 *   | <0.001  | 23 ± 27 *         | <0.001       | 35 ± 35 *    | <0.001      | <0.001  |
| Alcohol, g/day        | 15 ± 20 *         | 8 ± 11 *     | <0.001      | 13 ± 18 *   | <0.001  | 9 ± 12 *          | <0.001       | 16 ± 20 *   | <0.001    | 9 ± 12 *    | <0.001  | 16 ± 20 *         | <0.001       | 9 ± 12 *     | <0.001      | <0.001  |
| 17-item MedDiet Q score| 8.27 ± 1.62 *    | 8.36 ± 2.66 **| 0.005 | 8.19 ± 2.67 * | <0.001 | 8.88 ± 2.61 * | <0.001 | 7.66 ± 2.57 * | <0.001 | 9.07 ± 2.73 * | <0.001 | 9.09 ± 2.67 * | 7.65 ± 2.54 * | <0.001 |

**Table 3.** Food consumption according to total dietary fat and specific types of fat (g/day).

Abbreviations: FA, fatty acids; MedDiet Q, Mediterranean Diet Questionnaire; MUFA, monounsaturated fatty acids; PFA, polyunsaturated fatty acids; SFAs, saturated fatty acids. All values are means ± SDs unless otherwise indicated. All quartiles were included in the analysis. Pearson’s chi-square test was used for categorical variables, and 1-factor ANOVA was used for continuous variables. * p < 0.05 for between-group changes, after adjustment for multiple comparisons with the Bonferroni method. **No statistical significance after post hoc test.
Consumption of olive oil, nuts, total fish, and total meat increased significantly with increasing quintiles of total dietary fat intake, whereas consumption of fruits, vegetables, legumes, total cereals, dairy products, cookies, and alcohol decreased. Similar results were obtained when MUFA quintiles were assessed. In contrast, participants in the highest quintile of PUFA intake had higher consumption of vegetables and legumes but lower total meat consumption. Participants in the highest quintile of ω-3 FA intake had higher consumption of fruits, vegetables, legumes, and total meat; and highest quintile of ALA intake had higher consumption of vegetables but lower of fruits, legumes, total cereals and olive oil, as well as meat. Otherwise, participants in the highest quintile of SFA intake had lower consumption of fruits, vegetables, legumes, nuts, total fish, total cereals, and dairy products, but higher consumption of total meat and cookies. Highest quintile of TFA intake was also associated with higher consumption of total cereals, dairy products, total meat, cookies and alcohol but lower consumption of fruits and vegetables. Overall, participants in the highest quintile of total and all subtypes of dietary fat intake had a significantly higher MedDiet score, except for SFA and TFA intake.

Prevalence of hyperglycemia was significantly higher in the highest quintiles of total and all subtypes of dietary fat intake except for TFA and ALA intake. Prevalence of low HDL-c was also higher in participants with the highest quintile of total fat, PUFA and LA intake but lower in the highest quintiles of ω-3 FA, MUFA, SFA, and TFA intake; and abdominal obesity prevalence was higher in participants with the highest quintile of ALA intake. Contrarily, the prevalence of hypertriglyceridemia was lower in participants with high ω-3 FA intake. Hypertension prevalence did not differ significantly according to intake of any type of fat.

Multivariate adjusted Odds Ratios (ORs) for components of the MetS across quintiles of total dietary fat intake and several subtypes of dietary fat intake are presented in Table 4. After adjustment for potential confounders (i.e., age, sex, BMI, smoking habit, education, energy, and alcohol intake, adherence to the MedDiet and physical activity), the OR of hyperglycemia were 1.2–1.6 times higher from the fourth-fifth quintile (Q4–Q5) of total fat and MUFA intakes compared with the first quintile; the OR of hyperglycemia were 1.3–1.6 times higher from the third-fifth quintile (Q3–Q5) of SFA intake compared with the first quintile. However, the OR for ω-3 FA intake was 1.3 times higher only for the fifth quintile (Q5) compared with the first quintiles. The OR of low HDL-c was also 1.2 times higher for the fifth quintile of LA compared with the first quintile. Contrarily, the OR of hypertriglyceridemia were 0.7–0.8 times lower from the third quintiles (Q3–Q5) of SFA intake and the OR for ω-3 FA intake was 0.7 times lower only for the fifth quintile compared with the first quintiles.

Table 4. Association between total dietary fat and specific types of fat with the Metabolic Syndrome components (as dichotomous variables).

|                          | Quintiles 1 | Quintiles 2 | Quintiles 3 | Quintiles 4 | Quintiles 5 | p Value |
|--------------------------|-------------|-------------|-------------|-------------|-------------|---------|
| **Total fat**            |             |             |             |             |             |         |
| High blood pressure      | 1.00 (ref.) | 0.99 (0.73, 1.35) | 0.81 (0.61, 1.10) | 0.96 (0.71, 1.30) | 0.94 (0.69, 1.27) | 0.615   |
| Hyperglycemia            | 1.00 (ref.) | 0.94 (0.78, 1.12) | 1.13 (0.94, 1.36) | 1.23 (1.02, 1.48) | 1.55 (1.28, 1.88) | <0.001  |
| Hypertriglyceridemia     | 1.00 (ref.) | 0.81 (0.69, 0.95) | 0.88 (0.74, 1.03) | 0.87 (0.74, 1.02) | 0.90 (0.76, 1.06) | 0.153   |
| Low HDL-c                | 1.00 (ref.) | 1.06 (0.90, 1.25) | 1.19 (1.01, 1.40) | 1.20 (1.02, 1.42) | 1.14 (0.96, 1.34) | 0.133   |
| Abdominal obesity        | 1.00 (ref.) | 1.19 (0.81, 1.75) | 1.33 (0.90, 1.98) | 1.60 (1.06, 2.43) | 1.75 (1.15, 2.68) | 0.065   |
| **MUFA s**               |             |             |             |             |             |         |
| High blood pressure      | 1.00 (ref.) | 1.17 (0.86, 1.59) | 0.99 (0.73, 1.33) | 0.87 (0.65, 1.17) | 0.97 (0.72, 1.31) | 0.429   |
| Hyperglycemia            | 1.00 (ref.) | 0.97 (0.81, 1.16) | 0.98 (0.81, 1.17) | 1.26 (1.04, 1.52) | 1.45 (1.19, 1.75) | <0.001  |
| Hypertriglyceridemia     | 1.00 (ref.) | 0.93 (0.79, 1.09) | 0.91 (0.78, 1.07) | 0.99 (0.84, 1.16) | 0.98 (0.83, 1.15) | 0.741   |
| Low HDL-c                | 1.00 (ref.) | 1.07 (0.91, 1.26) | 1.10 (0.94, 1.30) | 1.18 (1.00, 1.38) | 1.14 (0.97, 1.34) | 0.359   |
| Abdominal obesity        | 1.00 (ref.) | 1.12 (0.76, 1.66) | 1.08 (0.73, 1.60) | 1.58 (1.04, 2.42) | 1.54 (1.01, 3.34) | 0.111   |
positively associated with the prevalence of impaired fasting glucose \[34,35\] and lately diagnosed or risk of diabetes through several mechanisms. In the state of insulin resistance, lipogenesis is between total fat intake and TD2M risk [38–42]. Therefore, dietary fats could a

\[\omega\]

decrease in the risk of hypertriglyceridemia among participants in the upper quintiles of SFA and an increase in the risk of low HDL-c levels among participants in the upper quintile of LA, and a significant risk. The most important finding of the present study is a significant increase in the risk of hyperglycemia of dietary fat intake with the components of MetS in a Mediterranean population at high cardiovascular risk.

**Table 4. Cont.**

| PUFAs | Quintiles | 1 | 2 | 3 | 4 | 5 | p Value |
|-------|-----------|---|---|---|---|---|---------|
| High blood pressure | 1.00 (ref.) | 0.94 (0.69, 1.28) | 0.89 (0.65, 1.20) | 0.87 (0.64, 1.17) | 0.93 (0.69, 1.27) | 0.902 |
| Low HDL-c | 1.00 (ref.) | 0.96 (0.81, 1.13) | 0.96 (0.82, 1.14) | 1.11 (0.94, 1.31) | 1.12 (0.95, 1.32) | 0.160 |
| Abdominal obesity | 1.00 (ref.) | 1.05 (0.70, 1.58) | 1.13 (0.74, 1.71) | 1.06 (0.71, 1.60) | 1.31 (0.86, 2.00) | 0.771 |

| SFAs | Quintiles | 1 | 2 | 3 | 4 | 5 | p Value |
|-------|-----------|---|---|---|---|---|---------|
| High blood pressure | 1.00 (ref.) | 0.86 (0.64, 1.15) | 1.10 (0.81, 1.50) | 1.08 (0.80, 1.47) | 0.95 (0.70, 1.28) | 0.432 |
| Low HDL-c | 1.00 (ref.) | 1.12 (0.95, 1.32) | 1.00 (0.84, 1.18) | 1.12 (0.94, 1.32) | 0.94 (0.79, 1.11) | 0.137 |
| Abdominal obesity | 1.00 (ref.) | 1.07 (0.72, 1.61) | 1.40 (0.91, 2.16) | 1.02 (0.66, 1.53) | 1.33 (0.87, 2.02) | 0.404 |

| Trans FA | Quintiles | 1 | 2 | 3 | 4 | 5 | p Value |
|----------|-----------|---|---|---|---|---|---------|
| High blood pressure | 1.00 (ref.) | 0.97 (0.72, 1.30) | 1.27 (0.92, 1.74) | 0.87 (0.64, 1.18) | 1.14 (0.81, 1.60) | 0.114 |
| Low HDL-c | 1.00 (ref.) | 0.99 (0.84, 1.16) | 1.02 (0.87, 1.21) | 0.92 (0.78, 1.10) | 0.89 (0.74, 1.07) | 0.489 |
| Abdominal obesity | 1.00 (ref.) | 1.68 (1.07, 2.64) | 1.28 (0.84, 1.95) | 1.34 (0.87, 2.07) | 1.44 (0.91, 2.30) | 0.256 |

| Linoleic acid | Quintiles | 1 | 2 | 3 | 4 | 5 | p Value |
|---------------|-----------|---|---|---|---|---|---------|
| High blood pressure | 1.00 (ref.) | 0.98 (0.72, 1.34) | 0.77 (0.57, 1.04) | 0.93 (0.68, 1.26) | 0.91 (0.67, 1.23) | 0.423 |
| Low HDL-c | 1.00 (ref.) | 0.90 (0.76, 1.06) | 1.08 (0.91, 1.27) | 1.14 (0.97, 1.34) | 1.18 (1.00, 1.39) | 0.099 |
| Abdominal obesity | 1.00 (ref.) | 1.14 (0.75, 1.73) | 1.11 (0.74, 1.69) | 1.12 (0.75, 1.69) | 1.19 (0.79, 1.79) | 0.939 |

| Linolenic acid | Quintiles | 1 | 2 | 3 | 4 | 5 | p Value |
|---------------|-----------|---|---|---|---|---|---------|
| High blood pressure | 1.00 (ref.) | 0.83 (0.61, 1.13) | 0.82 (0.59, 1.15) | 0.99 (0.69, 1.40) | 0.82 (0.59, 1.14) | 0.488 |
| Low HDL-c | 1.00 (ref.) | 1.00 (0.84, 1.19) | 0.97 (0.80, 1.16) | 0.94 (0.78, 1.14) | 1.04 (0.87, 1.25) | 0.822 |
| Abdominal obesity | 1.00 (ref.) | 1.54 (1.02, 2.33) | 1.36 (0.87, 2.12) | 1.20 (0.77, 1.89) | 1.53 (0.98, 2.41) | 0.219 |

| ω-3 FA | Quintiles | 1 | 2 | 3 | 4 | 5 | p Value |
|---------|-----------|---|---|---|---|---|---------|
| High blood pressure | 1.00 (ref.) | 0.97 (0.73, 1.26) | 1.45 (1.06, 1.99) | 0.93 (0.69, 1.35) | 1.05 (0.88, 1.26) | 0.744 |
| Low HDL-c | 1.00 (ref.) | 0.91 (0.77, 1.07) | 0.86 (0.73, 1.01) | 0.97 (0.82, 1.14) | 0.84 (0.71, 1.00) | 0.175 |
| Abdominal obesity | 1.00 (ref.) | 1.22 (0.81, 1.86) | 1.05 (0.70, 1.57) | 0.93 (0.62, 1.40) | 1.50 (0.95, 2.38) | 0.237 |

Abbreviations: CI, confidence interval; HDL-c, high density lipoprotein cholesterol; OR, odds ratio; ref., reference. Values are expressed as n (%) and OR (95% CI). Logistic regression analysis comparing the presence of Metabolic Syndrome and its components (independent variables) between quintiles of total dietary fat and specific types (dependent variable). Logistic regression analysis after adjustment for sex, age (continuous variable), body mass index (continuous variable), smoking habit (categorized variable), education (categorized variable), energy intake (continuous variable), alcohol intake (continuous variable), adherence to the Mediterranean Diet (continuous variable) and physical activity (continuous variable, expressed as MET-min/week). Patients who not responded the physical activity questionnaires and participants reporting outliers for total physical activity expressed as MET-min/week (at 3 or more standard deviations from the mean) were excluded from the analysis (i.e., 154 men and 196 women).

4. Discussion

In this cross-sectional study we evaluated the association of total dietary fat and specific subtypes of dietary fat intake with the components of MetS in a Mediterranean population at high cardiovascular risk. The most important finding of the present study is a significant increase in the risk of hyperglycemia among participants in the upper quintiles of total dietary fat, SFA, MUFAs, and ω-3 FA intake, a significant increase in the risk of low HDL-c levels among participants in the upper quintile of LA, and a significant decrease in the risk of hypertriglyceridemia among participants in the upper quintiles of SFA and ω-3 FA intakes.

Controversial results in relation to hyperglycemia and dietary fat intake associations have been observed in the literature. Our results are in accordance with those reporting that fat intake is positively associated with the prevalence of impaired fasting glucose [34,35] and newly diagnosed and undiagnosed T2DM [34,36,37]. Nevertheless, several studies did not highlight any association between total fat intake and TD2M risk [38–42]. Therefore, dietary fats could affect insulin resistance or risk of diabetes through several mechanisms. In the state of insulin resistance, lipogenesis is
inhibited and lipolysis is exalted in adipocytes, which increases concentrations of circulating fatty acids. Consequently, typical dyslipidaemia is characterized by elevated TG, lowered HDL-C, and small and dense LDL-C particles, established as a risk factor for CVD, and associated with hyperinsulinemia [43]. In the vascular-metabolic Clinica Universidad de Navarra (VM-CUN) cohort, the prediction ability of triglyceride-glucose index (TyG index) and fasting plasma glucose was compared to predict incident T2DM and reported that its predictive ability is better than that of the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) [44]. Moreover, the higher level of TyG index was significantly associated with an increased risk of incident T2DM [45] and developing CVD [46].

On the other hand, in our study high SFA intake and hyperglycemia were also positively associated. A recent systematic review also pointed out positive associations between SFA intake and insulin sensitivity in observational studies, but any association between SFA intake and incidence of T2DM in prospective studies [47]. Another systematic review and meta-analysis of observational studies did not find any association between SFA and T2DM [48]. The (Lipids, Genes and Metabolic Syndrome Study (LIPGENE study) showed that MetS subjects responded differently to dietary fat modification according to their homeostasis model assessment-insulin resistance (HOMA-IR) status. Insulin-resistant MetS subjects with the highest HOMA-IR decreased fasting insulin and HOMA-IR concentrations after consumption of a high MUFA (HMUFA) diet and high-complex carbohydrate (LFHCC) diet supplemented with long-chain n-3 PUFA diet, and these decreases in the two markers were significantly lower than with the high SFA (HSFA) diet. Conversely, fasting insulin and HOMA-IR concentrations increased in the least insulin-resistant group after consumption of a high SFA (HSFA) diet [49].

Our results also show a significant increase in the prevalence of hyperglycemia with increasing MUFA and ω-3 FA intake. However, our results could be attributed to lower consumption of fruits, vegetables, legumes, fiber, and a higher meat intake among participants with the highest MUFA intake but contrary to the participants with the lowest ω-3 FA intake. A recent systematic review and meta-analysis of randomized controlled feeding trials showed beneficial effects of MUFA and PUFA on glucose-insulin homeostasis. Replacement of 5% dietary energy from carbohydrates or SFA with 5% dietary energy from either MUFA or PUFA lowered glycosylated hemoglobin A1C (HbA1c) and HOMA-IR. Replacement of 5% dietary energy from carbohydrates, SFA, or MUFA with PUFA also showed beneficial effects on insulin secretion ability [50]. Therefore, the modification of an individual dietary pattern to regularly include foods rich in MUFA and PUFA, such as the MedDiet, can benefit individuals with MetS and hyperglycemia or T2DM [51].

We also found that the OR for hypertriglyceridemia was lower in the upper quintiles of SFA intake (Q3–Q5). Contrarily to our results, a positive association of SFA intake with serum TG has been found in the literature [52–55]. Otherwise, a previous systematic review pointed out that the replacement of 1% dietary energy from SFA with MUFA or PUFA lowered TG levels [56]. However, our results could be attributed to the synergistic effect of high olive oil consumption (a healthy source of MUFA) among participants with the highest SFA intake. However, other studies have not found significant association between MUFA and MetS components, such as hypertriglyceridemia [52,57].

The present study also showed a significant increase in risk of hypertriglyceridemia in the upper quintile of ω-3 FA intake. Accordingly, some studies have shown that the intake of ω-3 FA, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), be effective in reducing plasma TG concentrations [47,52,58,59]. Other authors have also reported that low fat diets enriched with PUFA or replaced by healthy sources of fats (fish, avocado, nuts, broccoli, thistle, olives, linseed, and canola oil, etc.) or healthy sources of carbohydrates (whole grains, legumes, vegetables, and fruits) also decreased TG levels [49,60–65].

A previous systematic review of clinical trials found that some studies have observed that various conjugated linoleic acid (CLA) isomers, administered as supplements or CLA-enriched products, decreases HDL-C [66]. Another systematic review pointed out an inverse association between LA intake and CHD risk [67]. Recently, Yanai et al. [68] pointed out that TFA is significantly associated
with reduction of HDL-c and coronary risks, whereas MUFA, plant sterols and stanols intake (except policosanol) may not affect HDL-c. Conversely, fish oils consumption, especially DHA consumption, may be favorably associated with HDL metabolism [68]. In our study, LA intake but not TFA was significantly associated with low HDL-c levels.

It is also noting that no association between TFA intake and components of MetS was observed in our population; perhaps it is due to the intake of this type of fat being low in the elderly Mediterranean population, who consume low amounts of processed food [69]. However, the consumption of TFA has been identified as an important and modifiable risk factor for CHD [70]. Emerging data suggest that TFA is associated with all causes of mortality, total CHD, and CHD mortality, probably because of higher levels of intake of industrial TFA (products of partial hydrogenation of vegetable oils) than ruminant TFA (meats and dairy products of cows, sheep, and goats) [48].

Lately, abdominal obesity and HTN are not significantly associated with dietary fat intake, although these results could be attributed to the high prevalence of both MetS components in our population. However, another study showed a significant rise in the risk of abdominal obesity (OR 1.61, CI 1.23–2.13) and HTN (OR 1.39, CI 1.06–1.81) with increasing fat intake [35]. Moreover, findings from the Food4Me study showed a strong association between fat intake (total fat, MUFA, and SFA) and obesity risk [71], which in agreement with two Cochrane meta-analyses [70,72] comparing the weight loss effects of a low fat diet with usual diet showed an effect size of −1.5 kg and was mirrored by reductions in BMI (−0.5 kg/m²) and WC (−0.3 cm). Otherwise, a high-quality, moderately high-fat eating pattern (especially unsaturated fatty acids: PUFA and MUFA) like the MedDiet may have beneficial effects on BW and obesity [73]. A recent meta-analysis also provided evidence that high MUFA diets, as well as the Dietary Approaches to Stop Hypertension (DASH) and Mediterranean diets, and supplementation with ω-3 FA (EPA+DHA) effectively lowers blood pressure [47]. No evidence of harmful effects of reducing SFA intakes on blood pressure has been observed in the literature [70].

Our results may help to highlight the fact that dietary recommendations should focus not on lowering the total fat content of the diet but rather on specific types of fats and carbohydrates and, more importantly, on specific foods and overall dietary patterns [9] for individuals at high CVD risk.

5. Strengths and Limitations

Our study also has various strengths. The large study sample is highly representative of Spanish older adults with MetS (n = 6560), and the use of a standardized protocol reduces information bias about food intake, socioeconomic and lifestyles variables. Some methodological limitations should be acknowledged. First, the cross-sectional study nature; thus, causal inferences cannot be drawn. Second, the FFQ, the source of information to assess dietary fat intake, could overestimate the intake of certain food groups even having been validated. Third, we excluded participants with energy intake out of predefined ranges, to avoid information bias [15]. Previously, in the PREDIMED study, 827 participants who had extreme values for total energy intake or any micronutrient intake out of the predefined values were also excluded in the nutritional adequacy analysis [15]. Moreover, the present findings cannot be extrapolated to other population groups given that our study participants are senior adults with overweight/obesity and MetS. Although there have been controversies regarding the criteria of MetS, the harmonizing worldwide criteria have been agreed on by international academic societies [15]. However, some professional societies have pointed out the limitations of MetS as clinical and epidemiologic too [74–76]. Finally, the overestimation of the prevalence ratios derived from the OR when logistic regression is applied.

6. Conclusions

These data suggest a potential different role of types of dietary fat on the MetS components of individuals at high cardiovascular risk. Our main findings suggest that the intake of dietary fat was associated with a higher risk of hyperglycemia. It is likely that the effects of dietary fat intake on cardiometabolic syndrome will be influenced by the combination of nutrients of the food consumed.
Therefore, the type of dietary fat should be considered for future dietary recommendations to decrease risk of MetS at a population level.

**Author Contributions:** All authors contributed to obtain data from the participants recruited in the PREDIMED-Plus survey. J.A.T., M.d.M.B. and A.J. wrote the first draft of the manuscript and all other authors gave additional suggestions. All authors approved final version of the manuscript.

**Funding:** The PREDIMED-Plus trial was supported by the official funding agency for biomedical research of the Spanish government, ISCIII through the Fondo de Investigación para la Salud (FIS), which is co-funded by the European Regional Development Fund (four coordinated FIS projects led by Jordi Salas-Salvadó and Josep Vidal, including the following projects: PI13/00673, PI13/00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/00728, PI13/01090, PI13/01056, PI14/01722, PI14/00636, PI14/00618, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI16/00473, PI16/00662, PI16/01873, PI16/01094, PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120, PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827, PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926), the Special Action Project entitled: Implementación y evaluación de una intervención intensiva sobre la actividad física Cohorte PREDIMED-PLUS grant to Jordi Salas-Salvadó, the European Research Council (Advanced Research Grant 2013-2018; 340918) grant to Miguel Ángel Martínez-Gonzalez, the Recercaixa grant to Jordi Salas-Salvadó (2013ACUP00194), grants from the Consejería de Salud de la Junta de Andalucía (PI0458/2013; PS0358/2016; PI0137/2018), the PROMETEO/2017/017 grant from the Generalitat Valenciana, the SERMENGRANT, and CIBEROBN and FEDER funds (CB06/03), ISCIII. International Nut & Dried Fruit Council – FESNAD No. 201302: Miguel Ángel Martínez-Gonzalez (PI). Alicia Julibert, Maria del Mar Bibiloni, Cristina Bouzas, Lucia Ugarriza and Josep A. Tur are granted by Grant of support to research groups no. 35/2011 (Balearic Islands Gov.; FEDER funds), EU-COST ACTION CA16112, and Fundació La Marató TV3 (Spain) project ref. 201630.10. None of the funding sources took part in the design, collection, analysis or interpretation of the data, or in the decision to submit the manuscript for publication. The corresponding authors had full access to all the data in the study and had final responsibility to submit for publication.

**Acknowledgments:** The authors especially thank the PREDIMED-Plus participants for their enthusiastic collaboration, the PREDIMED-Plus personnel for their outstanding support, and the personnel of all associated primary care centers for their exceptional effort. Centros de Investigación Biomédica en Red: Obesidad y Nutrición (CIBEROBN), Centros de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP) and Centros de Investigación Biomédica en Red: Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM) are initiatives of Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Food companies, Hojiblanca and Patrimonio Comunal Olivarero, donated extra-virgin olive oil and Almond Board of California, American Pistachio Growers and Paramount Farms donated nuts for the pilot study. We thank the PREDIMED-Plus Biobank Network as a part of the National Biobank Platform of the ISCIII for storing and managing the PREDIMED-Plus biological samples.

**Conflicts of Interest:** J.S.-S. reports serving on the board of and receiving grant support through his institution from International Nut and Dried Fruit Council; receiving consulting personal fees from Danone, Font Vella Lanjarón, Nuts for Life, and Eroski; and receiving grant support through his institution from Nut and Dried Fruit Foundation and Eroski. ER reports grants, non-financial support, and other fees from California Walnut Commission and Alexion; personal fees and non-financial support from Merck, Sharp & Dohme; personal fees, non-financial support and other fees from Aegerion, and Ferrer International; grants and personal fees from Sanofi Aventis; grants from Amgen and Pfizer and; personal fees from Akcea, outside of the submitted work. XP reports serving on the board of and receiving consulting personal fees from Sanofi Aventis, Amgen, and Abbott laboratories; receiving lecture personal fees from Esteve, Lacer and Rubio laboratories. MD-R reports receiving grants from the Diputacion Provincial de Jaén and the Caja Rural de Jaén. LD reports grants from Fundación Cerveza y Salud. All other authors declare no competing interest.

**Abbreviations**

ALA: α-linolenic acid; ANOVA: analysis of variance; BMI: body mass index; CHD: coronary heart disease; CI: confidence interval; CLA: conjugated linoleic acid; CVD: cardiovascular disease; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; erMedDiet: energy-restricted traditional Mediterranean Diet; FFQ: food frequency questionnaire; FQI: fat quality index; HDL-c: high-density lipoprotein cholesterol; HOMA-IR: homeostasis model assessment-insulin resistance; HTN: hypertension; LA: linoleic acid; MedDiet: Mediterranean diet; MetS: Metabolic Syndrome; MUFA: monounsaturated fatty acids; OR: odds ratio; PREDIMED: PREvención con DIeta MEDiterránea; PUFA: polyunsaturated fatty acids; RAPA: Rapid Assessment of Physical Activity Questionnaires; SD: standard deviations; SFA: saturated fatty acids; T2DM: type 2 diabetes mellitus; TFA trans-fatty acids; TG: triglyceride; UFA: unsaturated fatty acids; WC: waist circumference; ω-3 FA: ω-3 fatty acid.
References

1. Rowley, W.R.; Bezdol, C.; Arikan, Y.; Byrne, E.; Krohe, S. Diabetes 2030: Insights from yesterday, today, and future trends. Popul. Health Manag. 2017, 20, 6–12. [CrossRef] [PubMed]

2. Kelly, T.; Yang, W.; Chen, C.S.; Reynolds, K.; He, J. Global burden of obesity in 2005 and projections to 2030. Int. J. Obes. 2008, 32, 1431–1437. [CrossRef] [PubMed]

3. RTI International. Projections of Cardiovascular Disease Prevalence and Costs: 2015–2035. Available online: https://healthmetrics.heart.org/wp-content/uploads/2017/10/Projections-of-Cardiovascular-Disease.pdf (accessed on 10 December 2018).

4. Riaz, H.; Khan, M.S.; Siddiqi, T.J.; Usman, M.S.; Shah, N.; Goyal, A.; Khan, S.S.; Mookadam, F.; Krasuski, R.A.; Ahmed, H. Association Between Obesity and Cardiovascular Outcomes: A Systematic Review and Meta-analysis of Mendelian Randomization Studies. JAMA Netw. Open 2018, 1, e183788. [CrossRef] [PubMed]

5. Mozaffarian, D.; Ludwig, D.S. The 2015 US dietary guidelines: Lifting the ban on total dietary fat. JAMA 2015, 313, 2421–2422. [CrossRef] [PubMed]

6. Billingsley, H.E.; Carbone, S.; Lavie, C.J. Dietary Fats and Chronic Noncommunicable Diseases. Nutrients 2018, 10, 1385. [CrossRef]

7. Siri-Tarino, P.W.; Sun, Q.; Hu, F.B.; Krauss, R.M. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am. J. Clin. Nutr. 2010, 91, 535–546. [CrossRef] [PubMed]

8. Harcombe, Z.; Baker, J.S.; Di Nicolantonio, J.J.; Grace, F.; Davies, B. Evidence from randomised controlled trials does not support current dietary fat guidelines: A systematic review and meta-analysis. Open Heart 2016, 3, e000409. [CrossRef]

9. The United States Department of Health & Human Services; The U.S. Department of Agriculture. 2015–2020 Dietary Guidelines for Americans. 2015. Available online: https://health.gov/dietaryguidelines/2015/guidelines/ (accessed on 10 December 2018).

10. Bach-Faig, A.; Berry, E.M.; Lairon, D.; Reguant, J.; Trichopoulou, A.; Dernini, S.; Medina, F.X.; Battino, M.; Belahsen, R.; Miranda, G.; et al. Mediterranean Diet Foundation Expert Group.Mediterranean diet pyramid today. Sci. Cult. Updates Public Health Nutr. 2011, 14, 2274–2284. [CrossRef]

11. Malakou, E.; Linardakis, M.; Armstrong, M.E.G.; Zannidi, D.; Foster, C.; Johnson, L.; Papadaki, A. The Combined Effect of Promoting the Mediterranean Diet and Physical Activity on Metabolic Risk Factors in Adults: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Nutrients 2018, 10, 1577. [CrossRef]

12. Bloomfield, H.E.; Greer, N.; Kane, R.; Wilt, T.J. Effects on Health Outcomes of a Mediterranean Diet With No Restriction on Fat Intake. Ann. Intern. Med. 2017, 166, 378–379. [CrossRef]

13. Estruch, R.; Ros, E.; Salas-Salvadó, J.; Covas, M.I.; Corella, D.; Arós, F.; Gómez-Gracia, E.; Ruiz-Gutiérrez, V.; Fiol, M.; Lapetra, J.; et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N. Engl. J. Med. 2013, 368, 1279–1290. [CrossRef] [PubMed]

14. Martínez-González, M.A.; Buil-Cosiales, P.; Corella, D.; Bulló, M.; Fito, M.; Vioque, J.; Romaguera, D.; Martínez, J.A.; Wännergren, J.; López-Miranda, J.; et al. Cohort Profile: Design and methods of the PREMID-Plus randomized trial. Int. J. Epidemiol. 2018. [CrossRef] [PubMed]

15. Alberti, K.G.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.C.; James, W.P.; Loria, C.M.; Smith, S.C., Jr. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120, 1640–1645. [PubMed]

16. Sánchez-Tainta, A.; Zazpe, I.; Bes-Rastrollo, M.; Salas-Salvadó, J.; Bullo, M.; Sorlí, J.V.; Corella, D.; Covas, M.I.; Arós, F.; Gutierrez-Bedmar, M.; et al. Nutritional adequacy according to carbohydrates and fat quality. Eur. J. Nutr. 2016, 55, 93–106. [CrossRef] [PubMed]

17. Fernández-Ballart, J.D.; Piñol, J.L.; Zazpe, I.; Corella, D.; Carrasco, P.; Toledo, E.; Pérez-Bauer, M.; Martínez-González, M.A.; Salas-Salvadó, J.; Martín-Moreno, J.M. Relative validity of a semi-quantitative food-frequency questionnaire in an elderly Mediterranean population of Spain. Br. J. Nutr. 2010, 103, 1808–1816.
18. Martin-Moreno, J.M.; Boyle, P.; Gorgojo, L.; Maisonneuve, P.; Fernandez-Rodriguez, J.C.; Salvini, S.; Willett, W.C. Development and validation of a food frequency questionnaire in Spain. *Int. J. Epidemiol.* 1993, 22, 512–519. [CrossRef] [PubMed]

19. de la Fuente-Arrillaga, C.; Ruiz, V.Z.; Bes-Rastrollo, M.; Sampson, L.; Martínez-González, M.A. Reproducibility of an FFQ validated in Spain. *Public Health Nutr.* 2010, 13, 1364–1372. [CrossRef]

20. The National Academies of Sciences Engineering Medicine, Institute of Medicine (US). Food and Nutrition Board. Dietary Reference Intakes (DRIs): Estimated Average Requirements Values. Available online: http://nationalacademies.org/hmd~/~/media/Files/Nutrition/DRI-Tables/1_%20EARs.pdf?la=en (accessed on 6 November 2018).

21. The National Academies of Sciences Engineering Medicine, Institute of Medicine (US). Food and Nutrition Board. Dietary Reference Intakes (DRIs): Recommended Dietary Allowance and Adequate Intake Values, Vitamins and Elements. Available online: http://nationalacademies.org/hmd~/~/media/Files/Nutrition/DRI-Tables/2_%20RDA%20and%20AI%20Values_Vitamin%20and%20Elements.pdf?la=en (accessed on 6 November 2018).

22. Institute of Medicine (US). *Dietary Reference Intakes for Vitamin D and Calcium*; Ross, A.C., Taylor, C.L., Yaktine, A.L., Del Valle, H.B., Eds.; National Academies Press: Washington, DC, USA, 2011; Available online: https://www.ncbi.nlm.nih.gov/books/NBK56070/ (accessed on 6 November 2018).

23. Institute of Medicine (US); Subcommittee on Interpretation and Uses of Dietary Reference Intakes; Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. *DRI Dietary Reference Intakes: Applications in Dietary Assessment*; National Academies Press: Washington, DC, USA, 2000; Available online: https://www.ncbi.nlm.nih.gov/books/NBK222872/ (accessed on 6 November 2018).

24. Signorello, L.B.; Munro, H.M.; Buchowski, M.S.; Schlundt, D.G.; Cohen, S.S.; Hargreaves, M.K.; Blot, W.J. Estimating nutrient intake from a food frequency questionnaire: Incorporating the elements of race and geographic region. *Am. J. Epidemiol.* 2009, 170, 104–111. [CrossRef]

25. Schröder, H.; Fitó, M.; Estruch, R.; Martínez-González, M.A.; Corella, D.; Salas-Salavadó, J.; Lamuela-Raventós, R.; Ros, E.; Salaverria, I.; Fiol, M.; et al. A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. *J. Nutr.* 2011, 141, 1140–1145. [CrossRef]

26. Topolski, T.D.; LoGerfo, J.; Patrick, D.L.; Williams, B.; Walwick, J.; Patrick, M.B. The Rapid Assessment of Physical Activity (RAPA) among older adults. *Prev. Chronic Dis.* 2006, 3, A118.

27. Molina, L.; Sarmiento, M.; Peñafiel, J.; Donaire, D.; Garcia-Aymerich, J.; Gomez, M.; Ble, M.; Ruiz, S.; Frances, A.; Schröder, H.; et al. Validation of the Regicor Short Physical Activity Questionnaire for the Adult Population. *PloS ONE* 2012, 7, e0168148. [CrossRef] [PubMed]

28. Elosua, R.; García, M.; Aguilar, A.; Molina, L.; Covas, M.I.; Marrugat, J. Validation of the Minnesota Leisure Time Physical Activity Questionnaire In Spanish Women. Investigators of the MARATDON Group. *Med. Sci. Sports Exerc.* 2000, 32, 1431–1437. [CrossRef] [PubMed]

29. Elosua, R.; Marrugat, J.; Molina, L.; Pons, S.; Pujol, E. Validation of the Minnesota Leisure Time Physical Activity Questionnaire in Spanish men. *Am. J. Epidemiol.* 1994, 139, 1197–1209. [CrossRef] [PubMed]

30. Ainsworth, B.E.; Haskell, W.L.; Herrmann, S.D.; Meckes, N.; Bassett, D.R., Jr.; Tudor-Locke, C.; Greer, J.L.; Vezina, J.; Whitt-Glover, M.C.; Leon, A.S. 2011 Compendium of Physical Activities: A second update of codes and MET values. *Med. Sci. Sports Exerc.* 2011, 43, 1575–1581. [CrossRef] [PubMed]

31. Rosique-Esteban, N.; Díaz-López, A.; Martínez-González, M.A.; Corella, D.; Goday, A.; Martín, J.A.; Romaguera, D.; Vioque, J.; Arós, F.; García-Rios, A.; et al. Leisure-time physical activity, sedentary behaviors, sleep, and cardiometabolic risk factors at baseline in the PREDMED-PLUS intervention trial: A cross-sectional analysis. *PloS ONE.* 2017, 12, e0172253. [CrossRef] [PubMed]

32. Willet, W.C. *Nutritional Epidemiology*, 2nd ed.; Oxford University Press: New York, NY, USA, 1998.

33. Willet, W.C.; Howe, G.R.; Kushi, L.W. Adjustment for total energy intake in epidemiologic studies. *Am. J. Clin. Nutr.* 1997, 65, 1220S–1228S. [CrossRef] [PubMed]

34. Feskens, E.J.; Virtanen, S.M.; Räsänen, L.; Tuomilehto, J.; Stengård, J.; Pekkanen, J.; Nissinen, A.; Kromhout, D. Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. *Diabetes Care* 1995, 18, 1104–1112. [CrossRef] [PubMed]
35. Narasimhan, S.; Nagarajan, L.; Vaidya, R.; Gunasekaran, G.; Rajagopal, G.; Parthasarathy, V.; Unnikrishnan, R.; Anjana, R.M.; Mohan, V.; Sudha, V. Dietary fat intake and its association with risk of selected components of the metabolic syndrome among rural South Indians. *Indian J. Endocrinol. Metab.* 2016, 20, 47–54.

36. Thanopoulou, A.C.; Karamanos, B.G.; Angelico, F.V.; Assaad-Khalil, S.H.; Barbato, A.F.; Del Ben, M.P.; Djordjevic, P.B.; Dimitrijevic-Sreecovich, V.S.; Gallotti, C.A.; Katsilambros, N.L.; et al. Dietary fat intake as risk factor for the development of diabetes: Multinational, multicenter study of the Mediterranean Group for the Study of Diabetes (MGSD). *Diabetes Care* 2003, 26, 302–307. [CrossRef]

37. van de Laar, F.A.; van de Lisdonk, E.H.; Lucassen, P.L.; Tigchelaar, J.M.; Meyboom, S.; Mulder, J.; van den Hoogen, H.J.; Rutten, J.E.; van Weel, C. Fat intake in patients newly diagnosed with type 2 diabetes: A 4-year follow-up study in general practice. *Br. J. Gen. Pract.* 2004, 54, 177–182.

38. Hu, F.B.; van Dam, R.M.; Liu, S. Diet and risk of Type II diabetes: The role of types of fat and carbohydrate. *Diabetologia* 2001, 44, 805–817. [CrossRef] [PubMed]

39. Salmerón, J.; Hu, F.B.; Manson, J.E.; Stampfer, M.J.; Colditz, G.A.; Rimm, E.B.; Willett, W.C. Dietary fat intake and risk of type 2 diabetes in women. *Am. J. Clin. Nutr.* 2001, 73, 1019–1026. [CrossRef] [PubMed]

40. Meyer, K.A.; Kushi, L.H.; Jacobs, D.R.; Folsom, A.R. Dietary fat and incidence of type 2 diabetes in older Iowa women. *Diabetes Care* 2001, 24, 1528–1535. [CrossRef] [PubMed]

41. Alhazmi, A.; Stojanovski, E.; McEvoy, M.; Garg, M.L. Macronutrient intake and type 2 diabetes risk in middle-aged Australian women. Results from the Australian Longitudinal Study on Women’s Health. *Public Health Nutr.* 2014, 17, 1587–1594. [CrossRef] [PubMed]

42. Guasch-Ferré, M.; Becerra-Tomás, N.; Ruiz-Canela, M.; Corella, D.; Schröder, H.; Estruch, R.; Ros, E.; Arós, F.; Gómez-Gracia, E.; Fiol, M.; et al. Total and subtypes of dietary fat intake and risk of type 2 diabetes mellitus in the Prevención con Dieta Mediterránea (PREDIMED) study. *Am. J. Clin. Nutr.* 2017, 105, 723–735. [CrossRef] [PubMed]

43. Sánchez-Íñigo, L.; Navarro-González, D.; Pastrana-Delgado, J.; Fernández-Montero, A.; Martínez, J.A. Association of triglycerides and new lipid markers with the incidence of hypertension in a Spanish cohort. *J. Hypertens.* 2016, 34, 1257–1265. [CrossRef] [PubMed]

44. Navarro-González, D.; Sánchez-Íñigo, L.; Pastrana-Delgado, J.; Fernández-Montero, A.; Martínez, J.A. Triglyceride-glucose index (TyG index) in comparison with fasting plasma glucose improved diabetes prediction in patients with normal fasting glucose: The Vascular-Metabolic CUN cohort. *Prev. Med.* 2016, 86, 99–105. [CrossRef]

45. Navarro-González, D.; Sánchez-Íñigo, L.; Fernández-Montero, A.; Pastrana-Delgado, J.; Martínez, J.A. TyG Index Change Is More Determinant for Forecasting Type 2 Diabetes Onset Than Weight Gain. *Medicine* 2016, 95, e3646. [CrossRef]

46. Sánchez-Íñigo, L.; Navarro-González, D.; Fernández-Montero, A.; Pastrana-Delgado, J.; Martínez, J.A. The TyG index may predict the development of cardiovascular events. *Eur. J. Clin. Investig.* 2016, 46, 189–197. [CrossRef]

47. Siri-Tarino, P.W.; Chiu, S.; Bergeron, N.; Krauss, R.M. Saturated Fats Versus Polyunsaturated Fats Versus Carbohydrates for Cardiovascular Disease Prevention and Treatment. *Am. Rev. Nutr.* 2015, 35, 517–543. [CrossRef]

48. de Souza, R.J.; Mente, A.; Maroleanu, A.; Cozma, A.I.; Ha, V.; Kishibe, T.; Uleryk, E.; Budylovsky, P.; Schünemann, H.; Beyene, J.; et al. Intake of saturated and trans-unsaturated fattyacids and risk of all cause mortality, cardiovascular disease, and type2diabetes: Systematic review and meta-analysis of observational studies. *BMJ* 2015, 351, h3978. [CrossRef] [PubMed]

49. Yubero-Serrano, E.M.; Delgado-Lista, J.; Tierney, A.C.; Perez-Martínez, P.; Garcia-Rios, A.; Alcala-Diaz, J.F.; Castaño, J.P.; Tinahones, F.J.; Drevon, C.A.; Defoort, C.; et al. Insulin resistance determines a differential response to changes in dietary fat modification on metabolic syndrome risk factors: The LIPGENE study. *Am. J. Clin. Nutr.* 2015, 102, 1509–1517. [CrossRef] [PubMed]

50. Imamura, F.; Michi, R.; Wu, J.H.; de Oliveira Otto, M.C.; Otte, F.O.; Abioye, A.I.; Mozaffarian, D. Effects of SaturatedFat, PolyunsaturatedFat, MonounsaturatedFat, and CarbohydrateonGlucose-InsulinHomeostasis: A SystematicReview and Meta-analysis of Randomised Controlled Feeding Trials. *PLoS Med.* 2016, 13, e1002087. [CrossRef] [PubMed]

51. Via, M.A.; Mechanick, J.I. Nutrition in Type 2 Diabetes and the Metabolic Syndrome. *Med. Clin.* 2016, 100, 1285–1302. [CrossRef] [PubMed]
52. Ebbesson, S.O.; Tejero, M.E.; Nobmann, E.D.; Lopez-Alvarenga, J.C.; Ebbesson, L.; Romenesko, T.; Carter, E.A.; Resnick, H.E.; Devereux, R.B.; MacCluer, J.W.; et al. Fatty acid consumption and metabolic syndrome components: The GOCADAN study. *J. Cardiometab. Syndr.* 2007, 2, 244–249. [CrossRef]

53. Hekmatdoost, A.; Mirmiran, P.; Hosseini-Esfahani, F.; Azizi, F. Dietary fatty acid composition and metabolic syndrome in Iranian adults. *Nutrition* 2011, 27, 1002–1007. [CrossRef] [PubMed]

54. Shab-Bidar, S.; Hosseini-Esfahani, F.; Mirmiran, P.; Hosseinpour-Niazi, S.; Azizi, F. Fatty acid composition and risk of metabolic syndrome: Tehran Lipid and Glucose Study. *J. Nutr. Metab.* 2014, 27, 98–108. [CrossRef]

55. Hosseinpour-Niazi, S.; Mirmiran, P.; Fallah-ghohroudi, A.; Azizi, F. Combined effects of saturated fatty acids and unsaturated fatty acids on the metabolic syndrome: Tehran lipid and glucose study. *J. Health Popul. Nutr.* 2015, 33, 5. [CrossRef]

56. Mensink, R.P. *Effects of Saturated Fatty Acids on Serum Lipids and Lipoproteins: A Systematic Review and Regression Analysis*; World Health Organization: Geneva, Switzerland, 2016.

57. Noel, S.E.; Newby, P.K.; Ordovas, J.M.; Tucker, K.L. Adherence to an (n-3) fatty acid and risk of coronary heart disease, stroke, and diabetes mellitus: A systematic review and meta-analysis. *J. Clin. Med. Res.* 2015, 7, 145–149. [CrossRef]

58. Cicero, A.F.; Derosa, G.; Di Gregori, V.; Bove, M.; Gaddi, A.V.; Borghi, C. Omega 3 polyunsaturated fatty acids and risk of coronary heart disease: A systematic review and meta-analysis of prospective cohort studies. *Circulation* 2010, 121, 2271–2283. [CrossRef] [PubMed]
70. Hooper, L.; Martin, N.; Abdelhamid, A.; Davey Smith, G. Reduction in saturated fat intake for cardiovascular disease. *Cochrane Database Syst. Rev.* 2015, CD011737. [CrossRef] [PubMed]

71. Celis-Morales, C.; Livingstone, K.M.; Affleck, A.; Navas-Carretero, S.; San-Cristobal, R.; Martinez, J.A.; Marsaux, C.F.M.; Saris, W.H.M.; O’Donovan, C.B.; Forster, H.; et al. Food4Me Study. Correlates of overall and central obesity in adults from seven European countries: Findings from the Food4Me Study. *Eur. J. Clin. Nutr.* 2018, 72, 207–219. [CrossRef] [PubMed]

72. Hooper, L.; Abdelhamid, A.; Bunn, D.; Brown, T.; Summerbell, C.D.; Skea, C.M. Effects of total fat intake on body weight. *Cochrane Database Syst. Rev.* 2015, CD011834. [CrossRef]

73. Beulen, Y.; Martínez-González, M.A.; van de Rest, O.; Salas-Salvadó, J.; Sorlí, J.V.; Gómez-Gracia, E.; Fiol, M.; Estruch, R.; Santos-Lozano, J.M.; Schröder, H.; et al. Quality of Dietary Fat Intake and Body Weight and Obesity in a Mediterranean Population: Secondary Analyses within the PREDIMED Trial. *Nutrients* 2018, 10, 2011. [CrossRef] [PubMed]

74. Kahn, R.; Buse, J.; Ferrannini, E.; Stern, M.; American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2005, 28, 2289–2304. [CrossRef] [PubMed]

75. Simmons, R.K.; Alberti, K.G.; Gale, E.A.; Colagiuri, S.; Tuomilehto, J.; Qiao, Q.; Ramachandran, A.; Tajima, N.; Brajkovich Mirchov, I; Ben-Nakhi, A.; et al. The metabolic syndrome: Useful concept or clinical tool? Report of a WHO Expert Consultation. *Diabetologia* 2010, 53, 600–605. [CrossRef]

76. Oda, E. Metabolic syndrome: Its history, mechanisms, and limitations. *Acta Diabetol.* 2012, 49, 89–95. [CrossRef]